Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC3
REST API REST API
Homo sapiens
ERCC3 is differentially expressed in 216 experiments: 89 organism parts: cerebellum, testis, ... (87 more);, 163 disease states: normal, multiple myeloma, ... (161 more);, 62 cell types 230 cell lines 24 compound treatments and 61 other conditions.
Synonyms TFIIH, XPB, RAD25, BTF2, GTF2H
Orthologs ERCC3 (Gallus gallus)   ERCC3_BOVIN (Bos taurus)   Ercc3 (Rattus norvegicus)   ercc3 (Ciona intestinalis)   Ercc3 (Mus musculus)   SSL2 (Saccharomyces cerevisiae)   ercc3 (Danio rerio)   hay (Drosophila melanogaster)   NP_001123812.1 (Xenopus laevis)   ERCC3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, response to oxidative stress, DNA binding, protein localization, nucleotide-excision repair, 3'-5' DNA helicase activity, protein binding, DNA repair, regulation of transcription, DNA-dependent, damaged DNA binding, ATPase activity, protein N-terminus binding, nucleic acid binding, response to hypoxia, mRNA capping, transcription from RNA polymerase II promoter, transcription factor binding, GTP binding, ATP binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, RNA polymerase II carboxy-terminal domain kinase activity, DNA-dependent ATPase activity, peptide binding, nucleus, ATP-dependent DNA helicase activity, nucleotide binding, hydrolase activity, transcription initiation from RNA polymerase II promoter, protein C-terminus binding, nucleoplasm, cell cycle checkpoint, DNA topological change, protein kinase activity, transcription from RNA polymerase I promoter, helicase activity, nucleotide-excision repair, DNA incision, viral reproduction, transcription-coupled nucleotide-excision repair, ATP catabolic process, nucleotide-excision repair, DNA duplex unwinding, holo TFIIH complex, gene expression, UV protection, dATP binding, hair cell differentiation, interspecies interaction between organisms, transcription initiation from RNA polymerase I promoter, positive regulation of viral transcription, SSL2-core TFIIH complex, protein phosphorylation, termination of RNA polymerase I transcription, nucleotide-excision repair, DNA damage removal, transcription elongation from RNA polymerase II promoter, transcription elongation from RNA polymerase I promoter
InterPro Term XPGB_DNA_repair, Helicase_C, DEAD-like_helicase, Helicase/UvrB_dom
UniProt Accession P19447, F2Z2V4
Gene-Disease Assocation XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB, TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP
Search EB-eye ENSG00000163161
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-7540, E-GEOD-6919, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
HL-60
1
2
E-GEOD-24147, E-GEOD-96, E-GEOD-5258
DU4475
1
E-MTAB-37
U266
1
E-MEXP-1269
224 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13987, E-GEOD-21750, ... (29 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
centrocyte
1
E-GEOD-15271
CD34+ cell
1
E-MEXP-583
eosinophil
1
E-GEOD-3982
hematopoietic stem cell
1
E-MEXP-1403
stromal cell
1
E-GEOD-1460
56 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-2280, E-GEOD-5370, ... (49 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
lung adenocarcinoma
2
E-MTAB-62, E-GEOD-2514
multiple myeloma
1
2
E-MTAB-62, E-GEOD-2113, E-GEOD-6691
carcinoma in situ, bladder tumor
1
E-MTAB-62
ischemic cardiomyopathy
1
E-GEOD-1869
157 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, E-GEOD-15811, ... (18 experiments)

Factor Value U/D Experiments
hydroxyurea
1
E-GEOD-6431
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
Cxcl12
1
E-GEOD-7307
TNF
1
E-GEOD-15205
phenol
1
E-GEOD-6907
epidermal growth factor
1
E-GEOD-6462
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1563, E-GEOD-20499, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-22278, E-GEOD-10315

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-1082, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-12293, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.238 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM